Lexaria extends pharmaceutical partnership agreement through April 2026

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement with an unnamed pharmaceutical company through April 30, 2026. The original agreement was signed on September 4, 2024.

The extension allows the pharmaceutical partner additional time to receive and review data from Lexaria's Australian clinical study. The agreement maintains a temporary exclusive license for the pharmaceutical company to evaluate Lexaria's DehydraTECH drug delivery technology in pre-clinical settings.

Initial pre-clinical studies examining pharmacokinetics in animals were completed earlier in 2025. The pharmaceutical partner has requested to review safety, pharmacokinetic and efficacy data from Lexaria's independent Australian human clinical study GLP-1-H24-4, which is currently undergoing full sample and data analysis.

Lexaria expects to release final results from the Australian study before the end of the fourth quarter of 2025. The extension enables continued strategic planning discussions with the pharmaceutical company's human clinical development team.

DehydraTECH is Lexaria's patented drug delivery platform technology designed to improve oral drug absorption into the bloodstream. The company operates a licensed research laboratory and holds 54 granted patents with additional patents pending worldwide.

You May Also Be Interested In

• Barclays Downgrades Travelers (TRV) to Underweight
• BofA Securities Upgrades MarketAxess (MKTX) to Neutral
• Cannae Holdings names interim CFO after executive resignation